GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

Perfil de GSK plc



Símbolo de cotizaciónGSK

Nombre de la empresaGSK plc

Fecha de salida a bolsaMay 22, 1972

Director ejecutivoWaterhouse (Deborah)

Número de empleados68629

Tipo de seguridadDepository Receipt

Fin del año fiscalMay 22

Dirección980 Great West Road

CiudadBRENTFORD

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited Kingdom

Código postalTW8 9GS

Teléfono442080475000

Sitio Webhttps://www.gsk.com/

Símbolo de cotizaciónGSK

Fecha de salida a bolsaMay 22, 1972

Director ejecutivoWaterhouse (Deborah)

Ejecutivos de GSK plc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Hal V. Barron, M.D.

Non-Executive Director

604.64K

+0.01%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

514.76K

+0.13%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

45.58K

+0.90%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

4.94K

+0.83%

Dr. Jeannie Lee

Independent Non-Executive Director, Scientific & Medical Expert

3.50K

+0.77%

Ms. Maya Martinez-Davis

President, US

19.00

+52.63%

Mr. David S. Redfern

President - Corporate Development

Ms. Victoria Anne Whyte

Company Secretary

Mr. Phil C. Thomson

President - Global Affairs

Dame Emma N. Walmsley

Chief Executive Officer, Executive Director